107 phenotypes from 9 alleles in 10 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Cd19tm1(cre)Cgn/Cd19+ Tnfaip3tm2Ama/Tnfaip3+ involves: 129P2/OlaHsd * C57BL/6	decreased B cell apoptosis	J:163917
	increased autoantibody level	J:163917
	increased germinal center B cell number	J:163917
	increased immunoglobulin level	J:163917
	increased plasma cell number	J:163917
	increased susceptibility to autoimmune disorder	J:163917
Cd19tm1(cre)Cgn/Cd19+ Tnfaip3tm1.1Awai/Tnfaip3tm1.1Awai involves: 129P2/OlaHsd	decreased B-1a cell number	J:175422
	decreased B-1b cell number	J:175422
	decreased marginal zone B cell number	J:175422
	decreased mature B cell number	J:175422
	enlarged spleen	J:175422
	increased anti-nuclear antigen antibody level	J:175422
	increased B cell number	J:175422
	increased B cell proliferation	J:175422
	increased follicular B cell number	J:175422
	increased germinal center B cell number	J:175422
	increased IgA level	J:175422
	increased IgG2a level	J:175422
	increased IgM level	J:175422
	increased splenocyte number	J:175422
	increased T cell number	J:175422
Gt(ROSA)26Sortm9(cre/ESR1)Arte/? Tnfaip3tm1Homy/Tnfaip3tm1Homy involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac	abnormal blood cell morphology/development	J:212681
	abnormal circulating cytokine level	J:212681
	abnormal circulating interleukin level	J:212681
	abnormal liver morphology	J:212681
	normal hematopoietic system phenotype	J:212681
	increased apoptosis	J:212681
	increased circulating interferon-gamma level	J:212681
	increased circulating interleukin-1 beta level	J:212681
	increased circulating interleukin-6 level	J:212681
	increased circulating tumor necrosis factor level	J:212681
	increased susceptibility to xenobiotic induced morbidity/mortality	J:212681
	pale spleen	J:212681
	thymus atrophy	J:212681
Tnfaip3m1Apb/Tnfaip3m1Apb C57BL/6-Tnfaip3m1Apb	abnormal branching of the mammary ductal tree	J:324062
	abnormal estrous cycle	J:324062
	abnormal mammary gland development	J:324062
	abnormal mammary gland lobule morphology	J:324062
	CNS inflammation	J:324062
	decreased circulating luteinizing hormone level	J:324062
	decreased corpora lutea number	J:324062
	decreased fasting circulating glucose level	J:324062
	decreased secondary ovarian follicle number	J:324062
	delayed female fertility	J:324062
	enlarged lymph nodes	J:324062
	impaired mammary gland growth during pregnancy	J:324062
	increased circulating insulin level	J:324062
	increased circulating progesterone level	J:324062
	increased effector memory T-helper cell number	J:324062
	increased macrophage cell number	J:324062
	increased microglial cell activation	J:324062
	increased tumor necrosis factor (ligand) superfamily member 11 level	J:324062
	increased tumor necrosis factor receptor superfamily member 11b level	J:324062
	insulin resistance	J:324062
	prolonged diestrus	J:324062
	reduced female fertility	J:324062
	short estrus	J:324062
	uterus inflammation	J:324062
Tnfaip3tm1.1Gho/Tnfaip3tm1.1Gho involves: C57BL/6J	enlarged spleen	J:217021
	normal immune system phenotype	J:217021
	increased myeloid cell number	J:217021
	increased myeloid cell number in bone marrow	J:217021
Tnfaip3tm1.1Gvl/Tnfaip3tm1.1Gvl Tg(Vil1-cre)997Gum/0 B6.Cg-Tnfaip3tm1.1Gvl Tg(Vil1-cre)997Gum	abnormal response/metabolism to endogenous compounds	J:163410
	abnormal small intestine crypts of Lieberkuhn morphology	J:163410
	decreased colon length	J:163410
	diarrhea	J:163410
	impaired adaptive thermogenesis	J:163410
	increased circulating alanine transaminase level	J:163410
	increased circulating aspartate transaminase level	J:163410
	increased circulating interleukin-6 level	J:163410
	increased enterocyte apoptosis	J:163410
	increased susceptibility to induced colitis	J:163410
	increased susceptibility to induced morbidity/mortality	J:163410
	increased susceptibility to weight loss	J:163410
	increased susceptibility to xenobiotic induced morbidity/mortality	J:163410
	liver degeneration	J:163410
	rectal hemorrhage	J:163410
Tnfaip3tm1Ama/Tnfaip3tm1Ama involves: C57BL/6J	abnormal cytokine secretion	J:92694
	abnormal inflammatory response	J:92694
Tnfaip3tm1Ama/Tnfaip3tm1Ama Not Specified	decreased body size	J:92931
	increased granulocyte number	J:92931
	increased inflammatory response	J:92931
	increased lymphocyte cell number	J:92931
	increased macrophage cell number	J:92931
	increased susceptibility to induced morbidity/mortality	J:92931
	intestinal inflammation	J:92931
	joint inflammation	J:92931
	kidney inflammation	J:92931
	liver inflammation	J:92931
	postnatal lethality, incomplete penetrance	J:92931
	premature death	J:92931
	thick dermal layer	J:92931
	thick epidermis	J:92931
Tnfaip3tm1Homy/Tnfaip3tm1Homy Tg(Mx1-cre)1Cgn/? involves: 129S6/SvEvTac * C57BL/6J * CBA/J	abnormal B cell number	J:212681
	abnormal blood cell morphology/development	J:212681
	abnormal circulating cytokine level	J:212681
	abnormal circulating interleukin level	J:212681
	abnormal myelopoiesis	J:212681
	abnormal spleen morphology	J:212681
	anemia	J:212681
	cachexia	J:212681
	enlarged liver	J:212681
	enlarged lymph nodes	J:212681
	normal hematopoietic system phenotype	J:212681
	increased circulating interferon-gamma level	J:212681
	increased circulating interleukin-1 beta level	J:212681
	increased circulating interleukin-6 level	J:212681
	increased circulating tumor necrosis factor level	J:212681
	liver inflammation	J:212681
	lung inflammation	J:212681
	premature death	J:212681
Tnfaip3tm2Ama/Tnfaip3tm2Ama Cd19tm1(cre)Cgn/Cd19+ involves: 129P2/OlaHsd * C57BL/6	abnormal B cell activation	J:163917
	abnormal B cell morphology	J:163917
	abnormal B-1a B cell morphology	J:163917
	decreased B cell apoptosis	J:163917
	decreased B cell number	J:163917
	increased autoantibody level	J:163917
	increased B cell number	J:163917
	increased B cell proliferation	J:163917
	increased germinal center B cell number	J:163917
	increased IgG level	J:163917
	increased IgM level	J:163917
	increased immature B cell number	J:163917
	increased immunoglobulin level	J:163917
	increased interleukin-6 secretion	J:163917
	increased plasma cell number	J:163917
	increased susceptibility to autoimmune disorder	J:163917
	increased T cell number	J:163917
Tnfaip3tm3.1Ama/Tnfaip3tm3.1Ama C57BL/6J-Tnfaip3tm3.1Ama	abnormal chemokine secretion	J:203160
	decreased interleukin-6 secretion	J:203160
	enlarged spleen	J:203160
	normal growth/size/body region phenotype	J:203160
	increased B cell number	J:203160
	increased CD4-positive, alpha-beta T cell number	J:203160
	increased CD8-positive, alpha-beta T cell number	J:203160
	increased susceptibility to induced colitis	J:203160
	myeloid hyperplasia	J:203160
Tnfaip3tm4.1Ama/Tnfaip3tm4.1Ama C57BL/6J-Tnfaip3tm4.1Ama	abnormal chemokine secretion	J:203160
	decreased interleukin-6 secretion	J:203160
	enlarged spleen	J:203160
	normal growth/size/body region phenotype	J:203160
	increased B cell number	J:203160
	increased CD4-positive, alpha-beta T cell number	J:203160
	increased CD8-positive, alpha-beta T cell number	J:203160
	increased susceptibility to induced colitis	J:203160
	myeloid hyperplasia	J:203160